| Name | Title | Contact Details |
|---|---|---|
Gregory MacMichael |
Chief Technical Officer | Profile |
Scientia Advisors is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Theralogix is a Holmes, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children.
At TwinStrand Biosciences we are using Duplex Sequencing ™ Technology to detect ultra-rare variants that are invisible by other sequencing approaches. We are applying our technology to a new generation of high-accuracy clinical diagnostics and innovative tools for scientific discovery.